Key result
A loading dose of clopidogrel was non-inferior to ticagrelor for the composite of death, MI, stent thrombosis, or stroke at 30 days post-PCI in elderly patients.
Why the study?
The study aimed to compare the efficacy and safety of loading doses of clopidogrel with ticagrelor in elderly patients undergoing PCI for stable ischemic heart disease.
Does a loading dose of ticagrelor compared to clopidogrel reduce ischemic events in elderly patients aged 65 years or older undergoing PCI for stable ischemic heart disease?
RCT (n=600)
randomized
No
Does a loading dose of ticagrelor compared to clopidogrel reduce ischemic events in elderly patients aged 65 years or older undergoing PCI for stable ischemic heart disease?
In elderly patients undergoing PCI for stable ischemic heart disease, a loading dose of clopidogrel is non-inferior to ticagrelor for 30-day ischemic outcomes, with a significantly lower incidence of dyspnea.
Answers are grounded in this paper and cite their sources.
Supports clopidogrel loading as alternative in elderly post-PCI; extends RCT evidence to this high-bleeding-risk group.
This study aimed to compare the efficacy and safety of loading doses of clopidogrel with ticagrelor in elderly patients undergoing PCI in SIHD. Methods: A randomized controlled trial was conducted at Saidu Group of Teaching Hospitals from January 2019 to January 2020. 600 patients aged 65 years or older with SIHD who underwent PCI were randomized to receive either a loading dose of clopidogrel 600mg or ticagrelor 180mg. The primary endpoint was a composite of death, myocardial infarction, stent thrombosis, or stroke at 30 days post-PCI.Results: The incidence of the primary endpoint was similar in both groups (8.3% in the clopidogrel group vs. 8.2% in the ticagrelor group, P=0.95). There were no significant differences in the rates of individual components of the primary endpoint between the two groups. Bleeding events were also similar in both groups (4.8% in the clopidogrel group vs. 4.7% in the ticagrelor group, P=0.95). However, ticagrelor was associated with a significantly higher incidence of dyspnea (9.8% vs. 2.3%, P<0.001).Conclusion: In elderly patients undergoing PCI for SIHD, a loading dose of clopidogrel was found to be non-inferior to ticagrelor in terms of the composite endpoint of death, myocardial infarction, stent thrombosis, or stroke at 30 days post-PCI.
No takes yet. Share an insight, caveat, or question.
AKHUND et al. (2023) conducted an RCT in Stable Ischemic Heart Disease (SIHD) (n=600). Clopidogrel vs. Ticagrelor 180mg loading dose was evaluated on Composite of death, myocardial infarction, stent thrombosis, or stroke at 30 days post-PCI (p=0.95). A loading dose of clopidogrel was non-inferior to ticagrelor for the composite of death, MI, stent thrombosis, or stroke at 30 days post-PCI in elderly patients.
Synapse has enriched 10 related papers. Consider them for comparative context: